Transplantation Direct (Jul 2023)

Cytomegalovirus Immunity Assays Predict Viremia but not Replication Within the Lung Allograft

  • Jenny Li, MD,
  • Bradley J. Gardiner, MD,
  • Sanda Stankovic, PhD,
  • Clare V. L. Oates, BSc (Hons),
  • Yvonne Cristiano, RN,
  • Bronwyn J. Levvey, RN,
  • Andrew G. Brooks, PhD,
  • Gregory I. Snell, MD,
  • Glen P. Westall, MD, PhD,
  • Lucy C. Sullivan, PhD

DOI
https://doi.org/10.1097/TXD.0000000000001501
Journal volume & issue
Vol. 9, no. 7
p. e1501

Abstract

Read online

Background:. Cytomegalovirus (CMV) infection causes significant morbidity and mortality in lung transplant recipients. Current guidelines use pretransplant donor and recipient CMV serostatus to predict the risk of subsequent CMV replication and length of antiviral prophylaxis. Immunological monitoring may better inform the risk of CMV infection in patients, thereby allowing for improved tailoring of antiviral prophylaxis. In this study, we compared 2 commercially available assays, the QuantiFERON-CMV (QFN-CMV) and T-Track-CMV (enzyme-linked immunosorbent spot assay), to predict the risk of CMV disease in lung transplant recipients. Methods:. We performed CMV immunity assays on 32 lung transplant recipients at risk of CMV disease as defined by serostatus (CMV-seropositive recipients, n = 26; or CMV-seronegative lung transplant recipient receiving a CMV-seropositive donor organ, n = 6). QFN-CMV and T-Track were performed on peripheral blood mononuclear cells, and episodes of CMV replication in both serum and bronchoalveolar lavage were found to be correlated to the CMV immune assays. The predictive ability of the assays was determined using Kaplan–Meier curves. Results:. There was a degree of concordance between tests, with 44% of recipients positive for both tests and 28% negative for both tests; however, test results were discordant in 28% of cases. A negative result in either the QFN-CMV (P < 0.01) or T-Track (P < 0.05) assays was obtained in a significantly higher number of recipients who experienced CMV replication in the blood. Using these assays together gave higher predictability of CMV replication, with only 1 recipient experiencing CMV replication in the blood who obtained a positive test result for both assays. Neither assay was able to predict recipients who experienced CMV replication in the lung allograft. Conclusions:. Our study demonstrates that CMV immunity assays can predict viremia; however, the lack of association with allograft infection suggests that CMV-specific T-cell immunity in the circulation is not associated with the control of CMV replication within the transplanted lung allograft.